Cellectar Biosciences Inc  

(Public, NASDAQ:CLRB)   Watch this stock  
Find more results for Simon Pedder´┐Ż
-0.03 (-0.90%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.28 - 3.49
52 week 1.76 - 9.20
Open 3.49
Vol / Avg. 12,010.00/13,432.00
Mkt cap 25.24M
P/E     -
Div/yield     -
EPS -2.19
Shares 7.56M
Beta 0.07
Inst. own 48%
May 12, 2015
Q1 2015 Cellectar Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 24, 2015
Q4 2014 Cellectar Biosciences Inc Earnings Call - Webcast
Mar 24, 2015
Q4 2014 Cellectar Biosciences Inc Earnings Release
Mar 10, 2015
Cellectar Biosciences Inc at ROTH Conference
Feb 9, 2015
Cellectar Biosciences Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -70.79% -80.12%
Return on average equity -86.32% -130.27%
Employees 24 -
CDP Score - -


3301 Agriculture Dr
MADISON, WI 53716-4133
United States - Map
+1-617-2441616 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a biopharmaceutical company developing compounds for the treatment and imaging of cancer. The Company uses phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle. Its compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. Its products include I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent being evaluated in a Phase II glioblastoma imaging trial; I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. I-131-CLR1404 is in Phase Ib dose-escalation trial for patients with advanced solid tumors; CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Chad J. Kolean Chief Financial Officer, Vice President - Finance, Treasurer
Bio & Compensation  - Reuters
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
Bio & Compensation  - Reuters
Cameron Szakacs Ph.D. Vice President - Clinical Development
Age: 51
Bio & Compensation  - Reuters
J. Patrick Genn Vice President - Business Development
Age: 56
Bio & Compensation  - Reuters
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Paul L. Berns Independent Director
Age: 47
Bio & Compensation  - Reuters
John P. Neis Independent Director
Age: 57
Bio & Compensation  - Reuters